Drug Profile
ALLO 715
Alternative Names: ALLO-715; Anti-BCMA AlloCAR T; Anti-BCMA CAR T cell therapy - Allogene; UCARTBCMALatest Information Update: 26 Jun 2023
Price :
$50
*
At a glance
- Originator Cellectis
- Developer Allogene Overland Biopharm; Allogene Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 26 Jun 2023 Preclinical trials in Multiple myeloma in China (Parenteral) (Overland ADCT Biopharma pipeline, June 2023)
- 08 Mar 2023 Efficacy and adverse events data from a phase I trial in Multiple myeloma released by Cellectis
- 10 Dec 2022 Efficacy and safety data from phase I UNIVERSAL trial in Multiple myeloma presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)